News

The behavioral director at the Angelman Syndrome Clinic at Massachusetts General Hospital discussed the phase 3 NEPTUNE trial of gaboxadol, also known as OV101.

The professor of neurology at NYU Langone discussed cenobamate’s potential as a treatment option for patients who have uncontrolled seizures, as well as its ability to bring a high number of patients toward complete seizure freedom.

Neurology News Network for the week ending December 21, 2019.

Two lots of the oral seizure treatment have been recalled and should be returned to the manufacturer.

After resubmitting the NDA for apomorphine sublingual film (APL-130277), the FDA has set the new PDUFA action date of May 21, 2020.

The drug safety warning stems from a review of case reports and clinical studies that showed use of gabapentinoids with or without opioids is associated with serious breathing difficulties.

Compared to counterparts who did not exercise, those with cognitive impairments with no dementia risk factors improved in executive functioning when they exercised consistently over 6 months.

The results pave the way for a potential phase 3 trial to examine the effects of nilotinib in patients with Parkinson disease.

Nancy Foldvary, DO, MS, director of the Cleveland Clinic Sleep Disorder Center, discussed challenges faced when treating insomnia.

The medical director of the Comprehensive Stroke Center at Cleveland Clinic reviewed the timeline of administering various thrombolytic agents and the benefits they bring.

CENTAUR trial principal investigator Sabrina Paganoni, MD, PhD, discussed details of the phase 2 trial that helped investigators have the greatest chance of seeing a measurable treatment effect in patients with ALS.

The professor and chief of pediatric neurology, and director of the comprehensive epilepsy program and neuroscience institute at Le Bonheur Children’s Hospital, detailed his experience with patients treated with perampanel.

The third generation, high-affinity, selective small molecule CGRP receptor antagonist was significantly superior in the 2 higher doses on both co-primary end points of pain freedom and most bothersome symptoms.